Detail akcie Eledon Pharma Rg online

Business Summary: Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Eledon Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 42% to $35.2M. Lower net loss reflects Other income increase of 48% to $3.7M (income), Stock-based Compensation in SGA decrease of 3% to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.27 to -$0.46.